Transgenic News and Research

RSS

Neogen announces acquisition of GeneSeek

Neogen Corporation announced today that it had purchased all the outstanding shares of GeneSeek, Inc., of Lincoln, Neb. GeneSeek is considered the leading commercial agricultural genetics laboratory in the United States.

1 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

Plant-based system could help improve lives of hemophilic patients

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.

31 Mar 2010

Chromatin expands operations to 5,000 square foot facility in University of Illinois' Research Park

The University of Illinois today announces that Chromatin, Inc., a biotechnology company that has occupied space in the University's Research Park since 2005 as part of the EnterpriseWorks incubator, is expanding operations and graduating to a 5,000 square foot facility in the Research Park. The expansion marks the company's continued significant progress in commercializing its proprietary technology, including mini-chromosomes which were originally developed at the University of Chicago by company co-founder and CEO Daphne Preuss.

30 Mar 2010

Chakra Biotech completes MYR18.2m Series B investment round

Chakra Biotech Sdn Bhd, a Malaysian based Contract Research Organization, has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.

29 Mar 2010

FT and GGT enzymes can be promising targets for treatment of lung cancer

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

29 Mar 2010

Study on zebrafish regenerate tissues links human heart implications

In a paper published in the March 25, 2010 issue of Nature, researchers working at the Salk Institute for Biological Studies and the Center of Regenerative Medicine in Barcelona (CMRB) identified a fish heart cell population that is the source of this astonishing healing feat, a finding that could provide insight into how mammalian hearts might be coaxed into repairing themselves after injury brought on by heart attack.

25 Mar 2010

Experimental vaccine can help delay IBD and colon cancer

An experimental vaccine against an abnormal protein found in some tumors has the potential to delay the onset of inflammatory bowel disease (IBD) and in turn prevent progression to colon cancer, according to researchers at the University of Pittsburgh School of Medicine.

25 Mar 2010

'Doublesex' gene also sculpts brain and nervous system architecture leading to sex-specific behaviours

The brains of males and females, and how they use them, may be far more different then previously thought, at least in the fruit fly Drosophila melanogaster, according to research funded by the Wellcome Trust.

22 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Research focuses on DYRK1A gene in association with Down's syndrome

Research undertaken in recent years on Down's syndrome has focused on the DYRK1A gene. The superexpression of this gene affects transmission in the neurones, according to Mr Garikoitz Azkona. In his PhD thesis, The molecular bases of neuropathology in Down's syndrome: the role of DYRK1A, Mr Azkona argues that this failure in neurone transmission could be behind the problem that persons with Down's syndrome have regarding visual-spatial memory.

2 Mar 2010

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

2 Mar 2010

Using genetic engineering techniques in pigs, scientists create new model of diabetes

The incidence of diabetes is rising worldwide. Using genetic engineering techniques in pigs, scientists at Ludwig-Maximilians-Universität in Munich have created a new model of this metabolic disorder, which recapitulates many features of the disease, and promises to contribute significantly to improvements in diagnosis and therapy.

1 Mar 2010

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer’s disease (AD).

24 Feb 2010

LFB Biotechnologies provides new loan financing to GTC Biotherapeutics for key strategic programs

GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) announced that it has entered into an agreement with its strategic partner, LFB Biotechnologies (Les Ulis, France), pursuant to which LFB has agreed to provide $7 million of new loan financing to GTC.

23 Feb 2010

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

Neurotoxin study may help find new therapies to block hyperactive ion channels

There are approximately 500 species of cone snails, each producing 50 - 200 different conotoxins. A similar number of peptide toxins are produced by snakes, spiders, sea anemones, scorpions and other venomous animals. The animals use the neurotoxins to paralyze their prey.

11 Feb 2010

India puts indefinite 'moratorium' on release of country's first GM vegetable

"India has postponed the launch of its first genetically modified (GM) vegetable, saying it would adopt a cautious approach and wait for more scientific studies on the impact of the new variety of eggplant," Reuters reports (Majumdar, 2/9).